<doc>
  <docmeta id="113hr1285ih">
    <bill congress="113" type="hr" number="1285" version="ih"/>
    <revision size="4045" annotations="0" id="7" commit-time="2013-04-08T19:41:49+00:00" committer="favila" doc="113hr1285ih/7.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5053C6D58BD94732BD07C1A4A1C3AAC7" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 1285 IH: To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-03-20</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1285</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130320">March 20, 2013</action-date>
			<action-desc>
        <sponsor name-id="B001260">Mr. Buchanan</sponsor> (for
			 himself, <cosponsor name-id="M000133">Mr. Markey</cosponsor>,
			 <cosponsor name-id="C001047">Mrs. Capito</cosponsor>,
			 <cosponsor name-id="D000600">Mr. Diaz-Balart</cosponsor>,
			 <cosponsor name-id="D000533">Mr. Duncan of Tennessee</cosponsor>,
			 <cosponsor name-id="M000689">Mr. Mica</cosponsor>, <cosponsor name-id="R000582">Mr. Roe of Tennessee</cosponsor>,
			 <cosponsor name-id="R000395">Mr. Rogers of Kentucky</cosponsor>,
			 <cosponsor name-id="R000583">Mr. Rooney</cosponsor>,
			 <cosponsor name-id="R000435">Ms. Ros-Lehtinen</cosponsor>,
			 <cosponsor name-id="B000911">Ms. Brown of Florida</cosponsor>,
			 <cosponsor name-id="C000754">Mr. Cooper</cosponsor>,
			 <cosponsor name-id="E000290">Ms. Edwards</cosponsor>,
			 <cosponsor name-id="H000324">Mr. Hastings of Florida</cosponsor>,
			 <cosponsor name-id="K000375">Mr. Keating</cosponsor>,
			 <cosponsor name-id="L000562">Mr. Lynch</cosponsor>,
			 <cosponsor name-id="R000011">Mr. Rahall</cosponsor>,
			 <cosponsor name-id="W000808">Ms. Wilson of Florida</cosponsor>,
			 <cosponsor name-id="K000379">Mr. Kennedy</cosponsor>,
			 <cosponsor name-id="M001191">Mr. Murphy of Florida</cosponsor>,
			 <cosponsor name-id="C001066">Ms. Castor of Florida</cosponsor>,
			 <cosponsor name-id="D000616">Mr. DesJarlais</cosponsor>,
			 <cosponsor name-id="F000458">Mr. Fincher</cosponsor>,
			 <cosponsor name-id="M001144">Mr. Miller of Florida</cosponsor>,
			 <cosponsor name-id="N000185">Mr. Nugent</cosponsor>,
			 <cosponsor name-id="T000462">Mr. Tiberi</cosponsor>,
			 <cosponsor name-id="I000056">Mr. Issa</cosponsor>, <cosponsor name-id="D000610">Mr. Deutch</cosponsor>, <cosponsor name-id="P000599">Mr.
			 Posey</cosponsor>, <cosponsor name-id="B001273">Mrs. Black</cosponsor>,
			 <cosponsor name-id="P000588">Mr. Pearce</cosponsor>,
			 <cosponsor name-id="M001179">Mr. Marino</cosponsor>,
			 <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>,
			 <cosponsor name-id="W000796">Mr. Westmoreland</cosponsor>,
			 <cosponsor name-id="S001187">Mr. Stivers</cosponsor>,
			 <cosponsor name-id="B001271">Mr. Benishek</cosponsor>,
			 <cosponsor name-id="C001045">Mr. Crenshaw</cosponsor>,
			 <cosponsor name-id="R000593">Mr. Ross</cosponsor>, <cosponsor name-id="H001038">Mr. Higgins</cosponsor>, <cosponsor name-id="S001186">Mr.
			 Southerland</cosponsor>, <cosponsor name-id="T000470">Mr. Tipton</cosponsor>,
			 <cosponsor name-id="S001154">Mr. Shuster</cosponsor>,
			 <cosponsor name-id="M001150">Mrs. Miller of Michigan</cosponsor>,
			 <cosponsor name-id="D000619">Mr. Rodney Davis of Illinois</cosponsor>, and
			 <cosponsor name-id="S001179">Mr. Schock</cosponsor>) introduced the following
			 bill; which was referred to the <committee-name committee-id="HIF00">Committee
			 on Energy and Commerce</committee-name>, and in addition to the Committee on
			 the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a
			 period to be subsequently determined by the Speaker, in each case for
			 consideration of such provisions as fall within the jurisdiction of the
			 committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act to make any
		  substance containing hydrocodone a schedule II drug.</official-title>
	</form>
	<legis-body id="H64ADA54580D54D5781521F3E9A680C6C" style="OLC">
		<section id="HAE84EA22D64A40F39FBCE51322182962" section-type="section-one">
      <enum>1.</enum>
      <header>Hydrocodone
			 amendment</header>
			<subsection id="HCDBE11CD53D3465F8A3E3E2E4729C27B">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text display-inline="yes-display-inline">Schedule III(d) in
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:202">section 202 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>)</cato:entity> is amended
			 by—</text>
				<paragraph id="HB3F094DE09264E63BFDB26F6E70E4037">
          <enum>(1)</enum>
          <text display-inline="yes-display-inline">striking <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:202/p:3">paragraphs (3)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:202/p:4">(4)</cato:entity-ref>; and</text>
				</paragraph>
        <paragraph id="H3BD18BDC4D464BFFBF0D43AB5D2FE291">
          <enum>(2)</enum>
          <text display-inline="yes-display-inline">redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:202/p:5,6,7,8">paragraphs (5), (6), (7), and
			 (8)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:202/p:3,4,5,6" proposed="true">paragraphs (3), (4), (5), and (6)</cato:entity-ref>, respectively.</text>
				</paragraph>
      </subsection>
      <subsection id="HC80D098BF72044739952FAAE5BA22C95">
        <enum>(b)</enum>
        <header>Effective
			 date</header>
        <text>The amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="113 HR 1285/s:1/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall take effect on
			 the date that is 6 months after the date of enactment of this Act.</text>
			</subsection>
    </section>
    <section id="HB7F1B90519D9485CB23C23FD12614A22">
      <enum>2.</enum>
      <header>Physical security
			 requirements</header>
      <text display-inline="no-display-inline">Notwithstanding
			 the amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="113 HR 1285/s:1" proposed="true">section 1</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1500">Attorney General</cato:entity-ref> shall immediately,
			 without regard to <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code, amend section
			 1301.72 of title 21, Code of Federal Regulations, relating to the physical
			 security controls for non-practitioners, narcotic treatment programs and
			 compounders for narcotic treatment programs, and storage areas for controlled
			 substances, to allow, for the 3-year period beginning on the date of enactment
			 of this Act, manufacturers and distributors to store hydrocodone compound
			 products in accordance with the physical security requirements for schedule
			 III, IV, and V controlled substances.</text>
		</section>
    <section id="H372016F4F7B74037BE41276FC541AEBD">
      <enum>3.</enum>
      <header>GAO
			 report</header>
			<subsection id="H7C2E3A587D904B51A722E2823E0BB85A">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text display-inline="yes-display-inline">Not later than 18
			 months after the date of enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of the
			 United States</cato:entity-ref> shall submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report on the reclassification of
			 hydrocodone products under this Act.</text>
			</subsection>
      <subsection id="H1D45520BFA5A479B8C89BBEE7F77F8FF">
        <enum>(b)</enum>
        <header>Contents</header>
        <text>The
			 report required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="113 HR 1285/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall include—</text>
				<paragraph id="H5A9F4748FC234E6CBF663C7CD2EA456D">
          <enum>(1)</enum>
          <text>an assessment of
			 the degree to which the reclassification of hydrocodone products under this Act
			 impacts the ability of patients with legitimate medical needs, particularly
			 those in rural areas and nursing home facilities, to access adequate pain
			 management; and</text>
				</paragraph>
        <paragraph id="HFB3D55624EC24752861E876292895E6B">
          <enum>(2)</enum>
          <text>recommendations
			 necessary to address issues, if any, relating to patient access to adequate
			 pain management.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>